Cancer is one of the most common diseases and causes of death worldwide. Since common
treatment approaches do not yield acceptable results in many patients, develo** …

Highlights•Nanobodies (Nbs) are camelid-derived single-domain antibodies.•Nbs have
powerful binding and inhibitory capacity with great therapeutic potential.•Nbs are used in …

Single‐domain antibodies (sdAbs), the autonomous variable domains of camelid and shark
heavy‐chain antibodies, have many desirable properties as components of biologic drugs …

With more than 20 molecules in clinical use, monoclonal antibodies have finally come of age
as therapeutics, generating a market value of 11billionin2004,expectedtoreach 26 billion by …

Antibodies are important tools for experimental research and medical applications. Most
antibodies are composed of two heavy and two light chains. Both chains contribute to the …

With 23 approvals in the US and other countries and 4 approvals outside US, antibodies are
now widely recognized as therapeutic molecules. The therapeutic and commercial …

Targeted therapy and immunotherapy have become mainstream in cancer treatment.
However, only patient subsets benefit from these expensive therapies, and often responses …

Simple Summary B7-H3 costimulatory ligand has sparked tremendous interest as a target
for antibody-directed therapy of solid tumors. This is attributed to high expression of B7-H3 …

The low 5-year survival rate for patients with acute myeloid leukemia (AML), primarily
caused due to disease relapse, emphasizes the need for better therapeutic strategies …

In the last decade, cancer immunotherapies have produced impressive therapeutic results.
However, the potency of immunotherapy is tightly linked to immune cell infiltration within the …